We used a dual Aurora-A/Aurora-B inhibitor in combination with EGFR blockage through cetuximab and established an additive or possibly even synergistic effect on SCCHN cells in vitro. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.